Lungpacer Medical: Funding, Investors & Team (Sep 2026)
Lungpacer Medical is developing a novel therapeutic solution for preserving the integrity and strength of the diaphragm muscle The objective of the company is to develop and commercialize a novel therapeutic solution that addresses the significant health and cost issues associated with mechanical ventilation of critically ill patients in hospital Intensive Care Units (ICU). It is designed to activate the diaphragm using a temporary, minimally invasive, transvascular nerve stimulation approach that is expected to save many lives, improve surviving patient outcomes and greatly reduce hospital care costs. In addition, the paced diaphragm is expected to restore negative pressure ventilation, thereby potentially providing a more physiological respiratory pattern and reducing the levels of positive pressure ventilation and its harmful effects on the lungs. Lung Pacer was founded in 2009 and is headquartered in Vancouver, British Columbia, Canada.
Lungpacer Medical has raised $28.0M across 2 funding rounds on record, the most recent an undisclosed round of $12.0M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lungpacer Medical Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Lungpacer Medical Funding Rounds
Lungpacer Medical raised $16.0M in an undisclosed round announced in Jan 2021.
5.3 years later, an undisclosed round of $12.0M was announced in Apr 2026.
Lungpacer Medical Founders and Leadership Team
Contact details for the Lungpacer Medical team: 1 of 1 has an email address on file.
Start 14-day free trial →Lungpacer Medical Funding Compared to Other Biotechnology Startups
Lungpacer Medical's latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lungpacer Medical in Biotechnology and Vancouver
Companies Similar to Lungpacer Medical
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Lungpacer Medical Funding FAQs
What does Lungpacer Medical do?
Lungpacer Medical is developing a novel therapeutic solution for preserving the integrity and strength of the diaphragm muscle The objective of the company is to develop and commercialize a novel therapeutic solution that addresses the significant health and cost issues associated with mechanical ventilation of critically ill patients in hospital Intensive Care Units (ICU). It is designed to activate the diaphragm using a temporary, minimally invasive, transvascular nerve stimulation approach that is expected to save many lives, improve surviving patient outcomes and greatly reduce hospital care costs. In addition, the paced diaphragm is expected to restore negative pressure ventilation, thereby potentially providing a more physiological respiratory pattern and reducing the levels of positive pressure ventilation and its harmful effects on the lungs. Lung Pacer was founded in 2009 and is headquartered in Vancouver, British Columbia, Canada.
How much funding has Lungpacer Medical raised?
Lungpacer Medical has raised $28.0M across 2 rounds on record. The most recent is an undisclosed round of $12.0M announced in Apr 2026.
When did Lungpacer Medical last raise funding?
Lungpacer Medical's most recent funding round on record is an undisclosed round of $12.0M, announced in Apr 2026.
Who is the CEO of Lungpacer Medical?
Doug Evans is listed as CEO at Lungpacer Medical.
Where is Lungpacer Medical headquartered?
Lungpacer Medical is based in Vancouver, British Columbia, Canada.
How many employees does Lungpacer Medical have?
Lungpacer Medical is in the 51-100 employee band.
How does Lungpacer Medical's funding compare to other Biotechnology startups?
Lungpacer Medical's latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Lungpacer Medical Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lungpacer Medical is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.